| pubmed-article:11830462 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11830462 | lifeskim:mentions | umls-concept:C0042776 | lld:lifeskim |
| pubmed-article:11830462 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:11830462 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:11830462 | lifeskim:mentions | umls-concept:C0036576 | lld:lifeskim |
| pubmed-article:11830462 | lifeskim:mentions | umls-concept:C1547239 | lld:lifeskim |
| pubmed-article:11830462 | lifeskim:mentions | umls-concept:C1517499 | lld:lifeskim |
| pubmed-article:11830462 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
| pubmed-article:11830462 | lifeskim:mentions | umls-concept:C0441712 | lld:lifeskim |
| pubmed-article:11830462 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:11830462 | pubmed:dateCreated | 2002-2-6 | lld:pubmed |
| pubmed-article:11830462 | pubmed:abstractText | To modulate alloreactivity after hematopoietic stem cell transplantation, suicide gene-expressing donor T cells can be administered with an allogeneic T-cell-depleted bone marrow graft. Immune competence of such cells is a critical issue. The impact of the ex vivo gene transfer protocol (12-day culture period including CD3/interleukin-2 [IL-2] activation, retroviral-mediated gene transfer, and G418-based selection) on the anti-Epstein-Barr virus (EBV) potential of gene-modified cells has been examined. Cytotoxic (pCTL) and helper (pTh) cell precursor limiting dilution assays, interferon-gamma enzyme-linked immunospot, or fluorescence-activated cell sorter analysis after tetrameric HLA-A2/EBV peptide complexes revealed that the frequency of anti-EBV T cells was lower in gene-modified cells (GMCs) than in similarly cultured but untransduced T cells and was even lower than in fresh peripheral blood mononuclear cells, demonstrating both an effect of the culture and of the transduction or selection. The culture-dependent loss of EBV-reactive cells resulted from the preferential induction of activation-induced cell death in tetramer(+) cells. Replacing the initial CD3/IL-2 activation by CD3/CD28/IL-2 partially restored the anti-EBV response of GMCs by reducing the initial activation-induced cell death and enhancing the proliferation of EBV-tetramer(+) cells. Moreover, the G418 selection, and not the transduction, was directly toxic to transduced tetramer(+) cells. Replacing the G418 selection by an immunomagnetic selection significantly prevented the selection-dependent loss of EBV-specific cells. Overall, ex vivo gene modification of primary T cells can result in a significant reduction in EBV-reactive T cells through both culture-dependent and selection-dependent mechanisms. Improving immune functions of GMCs through modifications of the cell culture conditions and transduction/selection processes is critical for further clinical studies. | lld:pubmed |
| pubmed-article:11830462 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11830462 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11830462 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:11830462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11830462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11830462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11830462 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11830462 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:11830462 | pubmed:issn | 0006-4971 | lld:pubmed |
| pubmed-article:11830462 | pubmed:author | pubmed-author:LangFrançoisF | lld:pubmed |
| pubmed-article:11830462 | pubmed:author | pubmed-author:TiberghienPie... | lld:pubmed |
| pubmed-article:11830462 | pubmed:author | pubmed-author:FerrandChrist... | lld:pubmed |
| pubmed-article:11830462 | pubmed:author | pubmed-author:DuperrierAnne... | lld:pubmed |
| pubmed-article:11830462 | pubmed:author | pubmed-author:HervéPatrickP | lld:pubmed |
| pubmed-article:11830462 | pubmed:author | pubmed-author:SauceDelphine... | lld:pubmed |
| pubmed-article:11830462 | pubmed:author | pubmed-author:BodinierMarie... | lld:pubmed |
| pubmed-article:11830462 | pubmed:author | pubmed-author:GarinMarinaM | lld:pubmed |
| pubmed-article:11830462 | pubmed:author | pubmed-author:PetraccaBruno... | lld:pubmed |
| pubmed-article:11830462 | pubmed:author | pubmed-author:TonnelierNico... | lld:pubmed |
| pubmed-article:11830462 | pubmed:author | pubmed-author:MeloJunia VJV | lld:pubmed |
| pubmed-article:11830462 | pubmed:author | pubmed-author:ApperleyJane... | lld:pubmed |
| pubmed-article:11830462 | pubmed:author | pubmed-author:RobinetEricE | lld:pubmed |
| pubmed-article:11830462 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11830462 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:11830462 | pubmed:volume | 99 | lld:pubmed |
| pubmed-article:11830462 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11830462 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11830462 | pubmed:pagination | 1165-73 | lld:pubmed |
| pubmed-article:11830462 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11830462 | pubmed:meshHeading | pubmed-meshheading:11830462... | lld:pubmed |
| pubmed-article:11830462 | pubmed:meshHeading | pubmed-meshheading:11830462... | lld:pubmed |
| pubmed-article:11830462 | pubmed:meshHeading | pubmed-meshheading:11830462... | lld:pubmed |
| pubmed-article:11830462 | pubmed:meshHeading | pubmed-meshheading:11830462... | lld:pubmed |
| pubmed-article:11830462 | pubmed:meshHeading | pubmed-meshheading:11830462... | lld:pubmed |
| pubmed-article:11830462 | pubmed:meshHeading | pubmed-meshheading:11830462... | lld:pubmed |
| pubmed-article:11830462 | pubmed:meshHeading | pubmed-meshheading:11830462... | lld:pubmed |
| pubmed-article:11830462 | pubmed:meshHeading | pubmed-meshheading:11830462... | lld:pubmed |
| pubmed-article:11830462 | pubmed:meshHeading | pubmed-meshheading:11830462... | lld:pubmed |
| pubmed-article:11830462 | pubmed:meshHeading | pubmed-meshheading:11830462... | lld:pubmed |
| pubmed-article:11830462 | pubmed:meshHeading | pubmed-meshheading:11830462... | lld:pubmed |
| pubmed-article:11830462 | pubmed:meshHeading | pubmed-meshheading:11830462... | lld:pubmed |
| pubmed-article:11830462 | pubmed:meshHeading | pubmed-meshheading:11830462... | lld:pubmed |
| pubmed-article:11830462 | pubmed:meshHeading | pubmed-meshheading:11830462... | lld:pubmed |
| pubmed-article:11830462 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:11830462 | pubmed:articleTitle | Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. | lld:pubmed |
| pubmed-article:11830462 | pubmed:affiliation | INSERM E-0119/UPRES EA-2284, Etablissement Français du Sang- Bourgogne/Franche-Comté, Besançon, France. | lld:pubmed |
| pubmed-article:11830462 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11830462 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11830462 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11830462 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11830462 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11830462 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11830462 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11830462 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11830462 | lld:pubmed |
